Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731742 | PMC |
| http://dx.doi.org/10.3389/fnagi.2016.00009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Beyond Longer Intervals: Advocating for Regular Treatment of Neovascular AMD.
J Clin Med
December 2024
Division of Ophthalmology, Department of Surgery, UMass Chan-Lahey School of Medicine, Burlington, MA 01805, USA.
Personalizing the management of neovascular age-related macular degeneration (nAMD) poses significant challenges for practicing retina specialists and their patients. This commentary addresses some of these complexities, particularly those that arise in the context of an expanding array of intravitreal agents targeting vascular endothelial growth factor (VEGF) and related retinal disease targets. Many of these newer agents approved by the Food and Drug Administration (FDA) for the treatment of nAMD have labeling that indicates that they can provide non-inferior visual outcomes when compared head-to-head with previously available treatments and can be used at significantly extended dosing intervals in some patients.
View Article and Find Full Text PDFEconomic Burden of Late-Stage Age-Related Macular Degeneration in Bulgaria, Germany, and the US.
JAMA Ophthalmol
December 2024
Retina International, Dublin, Ireland.
Importance: Age-related macular degeneration (AMD) is a highly prevalent and debilitating retinal condition that affects more than 200 million people globally, with the severe late-stage forms-neovascular AMD (nAMD) and geographic atrophy (GA)-affecting more than 11 million people globally. However, much is unknown about the economic burden of the disease.
Objective: To estimate the economic burden associated with late-stage AMD in Bulgaria, Germany, and the US at the societal level.
Acceleration of age-related impairments in vascular function in women: interrogation of the (un)usual hormonal suspects.
Am J Physiol Heart Circ Physiol
December 2024
Department of Health and Human Physiology, University of Iowa, Iowa City, Iowa, United States.
Curcuma-Based Nutritional Supplements and Risk of Age-Related Macular Degeneration.
JAMA Ophthalmol
December 2024
Department of Ophthalmology, Byers Eye Institute, Horngren Family Vitreoretinal Center, Stanford University School of Medicine, Palo Alto, California.
Importance: Curcuma-based nutritional supplements (CBNS) are natural anti-inflammatory and antioxidant agents that may confer benefits against age-related macular degeneration (AMD).
Objective: To examine the association between the use of CBNS and the risk of development or progression of AMD.
Design, Setting, And Participants: This was a retrospective cohort study with data collection in June of 2024.
Tissue Plasminogen Activator or Perfluoropropane for Submacular Hemorrhage in Age-Related Macular Degeneration: A Factorial Randomized Clinical Trial.
JAMA Ophthalmol
December 2024
King's Ophthalmology Research Unit, Ophthalmology Department, King's College Hospital, London, United Kingdom.
Importance: Evidence is limited to support therapies to treat submacular hemorrhage (SMH) secondary to neovascular age-related macular degeneration (AMD) as an adjunct to anti-vascular endothelial growth factor therapy (anti-VEGF).
Objective: To determine if intravitreal tissue plasminogen activator (TPA) or gas improves visual acuity or promotes resolution of SMH secondary to neovascular AMD in eyes treated with ranibizumab.
Design, Setting, And Participants: This was a double-masked, sham-controlled, factorial randomized clinical trial and feasibility study that recruited participants from June 2014 to March 2019, with 12 months' follow-up.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!